Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network
Source: Finance News Network
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More16 Sep 2022 - eCargo Holdings Limited (ASX:ECG) Group CEO Laurence Lun discusses highlights from the company's interim results, operations during lockdown and future milestones.
Read More28 Aug 2020 - OptiScan Imaging Limited (ASX:OIL) Executive Chairman Darren Lurie provides an update on the company's sales, strategy, and its endomicroscopic imaging technology platform that allows for real-time virtual biopsies via the visualistation of living tissue.
Read More14 Aug 2025 - CEO and Managing Director Mark Freeman and Portfolio Manager David Grace discuss the FY25 full-year results of Australian Foundation Investment Company (ASX:AFI).
Read More27 Nov 2020 - Novatti Group Limited (ASX:NOV) Managing Director & CEO Peter Cook talks about the company's recently announced partnerships with UnionPay, Google Pay and Samsung Pay.
Read More25 Aug 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses reporting season and the lack of guidance from companies, cyclical businesses and M&A activity in the Energy sector.
Read More17 Mar 2022 - Managing Director Kym Winter-Dewhirst talks about Venice Energy's plans to develop the world’s first LNG import facility entirely powered by renewable energy. The LNG Import and Storage terminal will be located at Outer Harbor, around 14km from Adelaide, and has been designated as “essential infrastructure” by the South Australian State Government.
Read More30 Nov 2021 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow talks about the recent presentation of data from the CHM 1101 (Chlorotoxin CAR T) Phase 1 clinical trial in glioblastoma patients.
Read More14 Feb 2024 - Western Yilgarn Limited (ASX:WYX) General Manager Gavin Rutherford provides an introduction to the company, discussing its highly prospective nickle and platinum group elements tenements in Western Australia.
Read More23 Sep 2019 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director & CEO, Stephen Carter discusses the company's portfolio and the benefits of reformulating and delivering medication through the oral mucosa.
Read More
